Find a Doctor

GM
Areas of Expertise

Grant M. Mcarthur-Arthur

Peter Maccallum Cancer Centre
Male

Bio

Grant Mcarthur-Arthur is in Melbourne, Australia. They have been an author on 248 peer reviewed articles and participated in 1 clinical trial in the past 15 years.

Areas of Expertise

Contact

Melbourne, VIC, AU

Latest Research

Latest Advance
Study
  • Condition: Metastatic Merkel Cell Carcinoma (mMCC)
  • Journal: Journal for immunotherapy of cancer
  • Treatment Used: Immune Checkpoint Inhibitors (ICIs)
  • Number of Patients: 23
  • Published —
This study evaluated the effectiveness and safety of immune checkpoint inhibitors (stop the immune system from turning off before cancer is completely eliminated; ICIs) in patients with metastatic (has spread beyond the skin) Merkel cell carcinoma (rare and aggressive skin cancer; mMCC).
Latest Advance
Study
  • Condition: BRAF-mutated Metastatic Melanoma
  • Journal: Journal of translational medicine
  • Treatment Used: Dacarbazine or Vemurafenib?±?Cobimetinib
  • Number of Patients: 0
  • Published —
The study researched the safety and effectiveness of Dacarbazine or Vemurafenib?±?Cobimetinib for patients with BRAF-mutated metastatic melanoma.
Latest Advance
Study
  • Condition: BRAF-Mutant Melanoma
  • Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
  • Treatment Used: Vemurafenib and Cobimetinib
  • Number of Patients: 63
  • Published —
This study reported on the long-term outcomes of vemurafenib plus cobimetinib in patients with BRAF-mutant melanoma.
Latest Advance
Study
  • Condition: Advanced Melanoma
  • Journal: The New England journal of medicine
  • Treatment Used: Combined Nivolumab and Ipilimumab
  • Number of Patients: 0
  • Published —
This study reported outcomes for nivolumab plus ipilimumab or nivolumab alone in patients with advanced melanoma.
Latest Advance
Study
  • Condition: BRAFV600-Mutated Metastatic Melanoma
  • Journal: British journal of cancer
  • Treatment Used: Vemurafenib or Cobimetinib plus Vemurafenib
  • Number of Patients: 0
  • Published —
This study investigated the prognostic value of depth of response in two cohorts of patients with BRAFV600-mutated metastatic melanoma treated with vemurafenib or cobimetinib plus vemurafenib.
Latest Advance
Study
  • Condition: Patients with BRAFV600 Mutation-Positive Metastatic Melanoma Treated with Vemurafenib ± Cobimetinib
  • Journal: European journal of cancer (Oxford, England : 1990)
  • Treatment Used: Concomitant Dosing with Acid-Reducing Agents (ARAs) and Vemurafenib
  • Number of Patients: 920
  • Published —
This study evaluated the impact of concomitant acid-reducing agents (ARAs) and vemurafenib dose on the efficacy of vemurafenib in patients with BRAFV600 mutation-positive unresectable or metastatic melanoma treated with vemurafenib or cobimetinib plus vemurafenib.
Latest Advance
Study
  • Condition: Refractory solid tumors
  • Journal: Cancer chemotherapy and pharmacology
  • Treatment Used: Panobinostat
  • Number of Patients: 9
  • Published —
This study sought to describe dose limiting toxicities (DLT), pharmacokinetic (PK) profile, anti-tumor activity as well as biologic activity in pediatric patients taking panobinostat for refractory solid tumors.
Latest Advance
Study
  • Condition: Metastatic melanoma
  • Journal: Annals of oncology : official journal of the European Society for Medical Oncology
  • Treatment Used: Vemurafenib
  • Number of Patients: 675
  • Published —
This study evaluated the effects of vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma.

Clinical Trials

Clinical Trial
  • Status: Recruiting
  • Phase: Phase 2
  • Intervention Type: Drug, Radiation, Other
  • Participants: 218
  • Start Date: August 14, 2019
A Phase II, Open Label, Randomised, Controlled Trial of Ipilimumab and Nivolumab With Concurrent Intracranial Stereotactic Radiotherapy Versus Ipilimumab and Nivolumab Alone in Patients With Melanoma Brain Metastases.

All Publications
View All

Publication
Study
  • Journal: Journal for immunotherapy of cancer
  • Published —
Clinical, FDG-PET and molecular markers of immune checkpoint inhibitor response in patients with metastatic Merkel cell carcinoma.
Publication
Study
  • Journal: European journal of cancer (Oxford, England : 1990)
  • Published —
Management of melanoma brain metastases: Evidence-based clinical practice guidelines by Cancer Council Australia.

Contact

Melbourne, VIC, AU

Insurance

Contact them to find out if they accept your insurance plan.